GlobeNewswire Inc | Feb 9, 2021 04:30PM EST

February 09, 2021

BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 second quarter financial results after market close on Tuesday, February 16, 2021. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Companys website at www.ibioinc.com under News and Events in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and referencing conference code: 7891625.

About iBio, Inc.

iBio is a global leader in plant-based biologics manufacturing. ItsFastPharmingSystem combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others. The Companys subsidiary, iBio CDMO LLC, providesFastPharmingContract Development and Manufacturing Services along with the GlycaneeringDevelopment Services for the control and tailoring of N-glycosylation. For more information, visit www.ibioinc.com.

Contact:

Stephen KilmeriBio, Inc.Investor Relations(646) 274-3580skilmer@ibioinc.com